Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Construction in Progress (2017 - 2023)

CytomX Therapeutics' Construction in Progress history spans 7 years, with the latest figure at $368000.0 for Q4 2023.

  • For Q4 2023, Construction in Progress fell 47.8% year-over-year to $368000.0; the TTM value through Dec 2023 reached $368000.0, down 47.8%, while the annual FY2023 figure was $368000.0, 47.8% down from the prior year.
  • Construction in Progress reached $368000.0 in Q4 2023 per CTMX's latest filing, down from $705000.0 in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $705000.0 in Q4 2022 to a low of $236000.0 in Q4 2019.
  • Average Construction in Progress over 5 years is $373800.0, with a median of $308000.0 recorded in 2021.
  • Peak YoY movement for Construction in Progress: crashed 69.94% in 2019, then soared 128.9% in 2022.
  • A 5-year view of Construction in Progress shows it stood at $236000.0 in 2019, then grew by 6.78% to $252000.0 in 2020, then increased by 22.22% to $308000.0 in 2021, then skyrocketed by 128.9% to $705000.0 in 2022, then tumbled by 47.8% to $368000.0 in 2023.
  • Per Business Quant, the three most recent readings for CTMX's Construction in Progress are $368000.0 (Q4 2023), $705000.0 (Q4 2022), and $308000.0 (Q4 2021).